Why the study?
What is the optimal lifelong hypolipidemic treatment strategy for patients with heterozygous familial hypercholesterolemia?
Population
Patients with heterozygous familial hypercholesterolemia
Design
Review
Authors
Loading...
Supports stepwise lipid-lowering from infancy in HeFH; leaves open prospective validation of targets and sequencing.
What is the optimal lifelong hypolipidemic treatment strategy for patients with heterozygous familial hypercholesterolemia?
Lifelong, progressive hypolipidemic treatment starting in infancy is necessary to manage heterozygous familial hypercholesterolemia and prevent early atherosclerotic changes.
Vuorio et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: